Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
EHRA 2019: EHRA Type 2 Definition
Author(s): Line Melgaard Added: 5 years ago
Dr Line Melgaard (Aalborg University, Aalborg, DK) discusses the thromboembolic risk in patients with atrial fibrillation and valvular heart disease according to the EHRA Type 2 definition. Filmed on site at EHRA 2019 by Radcliffe Cardiology Questions: 1. What was the need to evaluate atrial fibrillation patients specifically with valvular heart disease? 2. How was the study set up to… View more

Anticoagulation

Electrophysiology & Arrhythmia
ACC 2018: Canagliflozin & heart failure in type 2 diabetes
Author(s): Gemma Figtree Added: 6 years ago
Gemma Figtree discusses the CANVAS trial - canagliflozin and heart failure in type 2 diabetes mellitus. Filmed by Radcliffe Cardiology on-site at the American College of Cardiology congress 2018 in Orlando, USA. View more

Heart Failure

Prevention & Chronic Conditions
TWILIGHT-Stent: Ticagrelor Monotherapy According to Stent Type
Author(s): George D Dangas Added: 2 years ago
Dr George Dangas (Mount Sinai Hospital, New York, NY, US) discusses the results of the TWILIGHT-Stent trial, presented at ESC 2021. This study examined the incidence of ischemic and bleeding events in patients treated with contemporary drug-eluting stents over 3-15 months. This trial also examined ticagrelor monotherapy vs ticagrelor with aspirin. Questions: 1. What were the main aims of… View more

Anticoagulation

Intervention
EASD 23: Efinopegdutide in NAFLD & T2D patients
Author(s): Samuel S Engel Added: 6 months ago
EASD 2023 — In this short interview, Dr Samuel S Engel (Associate Vice President at Merck) discusses a study investigating the effectiveness and safety of efinopegdutide (MK-6024) in patients with nonalcoholic fatty liver disease and type 2 diabetes (NCT04944992).The phase IIa study randomized 145 participants (efinopegdutide, n = 72; semaglutide, n = 73). The majority (55.2%) of participants… View more

Prevention & Chronic Conditions
Author(s): Christian Müller Added: 3 years ago
B-type natriuretic peptide (BNP) and N-terminal prohormone brain natriuretic peptide (NT-proBNP) have been shown to be extremely helpful in the diagnosis and management of patients with heart failure (HF). These neurohormones are secreted from both the left and the right cardiac ventricle in response to ventricular volume expansion and pressure overload. BNP and NT-proBNP can be seen as… View more

Heart Failure
Author(s): Christian Müller Added: 3 years ago
B-type natriuretic peptide (BNP) and N-terminal prohormone brain natriuretic peptide (NT-proBNP) have been shown to be extremely helpful in the diagnosis and management of patients with heart failure (HF). These neurohormones are secreted from both the left and the right cardiac ventricle in response to ventricular volume expansion and pressure overload. BNP and NT-proBNP can be seen as… View more

Heart Failure
Author(s): Lars Rydén , Linda Mellbin , Klas Malmberg Added: 3 years ago
The worldwide prevalence of diabetes in 2010 is already at epidemic proportions with an estimated 284.6 million adults (aged 20–79 years), representing 6.4% of the global adult population.1 However, more worryingly, the prevalence has increased by 15% since 20072 and projections estimate that 438.4 million adults will have diabetes in 2030, a 54% increase on 2010 figures.1 This drastic rise in… View more

Prevention & Chronic Conditions
EASD 22: SURMOUNT-MMO: Tirepatide in Obese Type II Diabetes Patients
Author(s): Steven E Nissen Added: 1 year ago
EASD 22 - Dr Steven Nissen (Cleveland Clinic, US) joins us to discuss the findings of the SURMOUNT-MMO trial. This study aimed to evaluate the effect of tirzepatide in type II diabetes patients who have obesity, or are overweight. Questions: 1. What was the rationale behind this study? 2. What is the mechanism of action of Tirzepatide? 3. What was the study design? 4. What were the main outcomes… View more

Prevention & Chronic Conditions
AHA 22: BT001 PIVOTAL: nCBT in Pts with Type II Diabetes
Author(s): Marc P Bonaca Added: 1 year ago
AHA 22 - Dr Marc Bonaca (University of Colorado School of Medicine, Aurora, Colorado, US) joins us to discuss the findings of the BT001 Pivotal Trial, originally presented at AHA 2022. BT001 Pivotal aimed to study the use of a mobile app that delivered nutritional cognitive behavioural therapy (nCBT) for the treatment of type II diabetes. The application targets behaviours which are associated… View more

Digital Health

Prevention & Chronic Conditions
Type 2 MI and Myocardial Injury in the Era of High-sensitivity Troponin
Author(s): Rifly Rafiudeen , Peter Barlis , Harvey D White , et al Added: 2 years ago

Vascular Disease and Surgery